









Markets
/
Stocks
/
nasdaq-cldx
/

Celldex Therapeutics Inc

CLDX

25.468USD

+1.008+4.12%

Market hours （ET）Quotes delayed by 15 min

1.69BMarket Cap

LossP/E TTM



Celldex Therapeutics Inc

25.468

+1.008+4.12%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

54 / 507

Overall Ranking

156 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 14 analysts

Buy

Current Rating

56.250

Target Price

+128.84%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 197.84% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 7.02M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 40.54.

Undervalued

The company’s latest PE is -8.11, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 75.86M shares, decreasing 15.48% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 3.94M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.51.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 5.80, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 730.00K, representing a year-over-year decrease of 70.78%, while its net profit experienced a year-over-year decrease of 57.92%.

Score

Industry at a Glance

Previous score

5.85

Change

-0.05



Financials

6.50

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.36

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.45

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -8.11, which is -10.83% below the recent high of -7.23 and 6.26% above the recent low of -7.60.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 54/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.29, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Celldex Therapeutics Inc is 59.50, with a high of 90.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

8.29

Change

Support & Resistance

No Data

Analyst Rating

Based on 14 analysts

Buy

Current Rating

56.250

Target Price

+128.84%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Celldex Therapeutics Inc

CLDX

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 8.77, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 26.76 and the support level at 21.26, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.78

Change

-0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.279

Buy

RSI(14)

57.086

Neutral

STOCH(KDJ)(9,3,3)

66.358

Sell

ATR(14)

1.163

High Vlolatility

CCI(14)

81.973

Neutral

Williams %R

33.894

Buy

TRIX(12,20)

0.348

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

24.638

Buy

MA10

24.150

Buy

MA20

23.164

Buy

MA50

22.934

Buy

MA100

21.643

Buy

MA200

22.003

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 114.26%, representing a quarter-over-quarter increase of 0.71%. The largest institutional shareholder is The Vanguard, holding a total of 3.94M shares, representing 5.94% of shares outstanding, with 1.87% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Kynam Capital Management LP

6.50M

+28.35%

Wellington Management Company, LLP

8.35M

-6.93%

BlackRock Institutional Trust Company, N.A.

4.62M

-0.64%

Fidelity Management & Research Company LLC

3.89M

+12.80%

The Vanguard Group, Inc.

Star Investors

3.89M

+0.42%

T. Rowe Price Associates, Inc.

Star Investors

3.35M

-4.13%

Commodore Capital LP

3.35M

+4.69%

Bellevue Asset Management AG

3.07M

Point72 Asset Management, L.P.

Star Investors

2.62M

+4.18%

State Street Global Advisors (US)

2.81M

-13.25%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.20, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.32. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.